Shares of drugmaker Novo Nordisk (NVO) sold off sharply last week, falling as much as 29% intraday Friday (before closing down 17%) and wiping out nearly $100B of market value in the process when ...

Since Ozempic blasted onto the stage in 2017 with its approval for type 2 diabetes, drugmakers Novo Nordisk and Eli Lilly have been battling to leapfrog each other with newer and more effective ...

Shares in Novo Nordisk have fallen by more than a quarter after the Ozempic maker revealed a set of underwhelming results in a trial for its next-generation obesity drug. A drop of 29pc led to as ...

Novo Nordisk's stock suffered its biggest one-day slide on record after its latest obesity drug trial disappointed investors hoping for another blockbuster weight-loss drug. The Ozempic-maker's ...

(CNN) — Since Ozempic blasted onto the stage in 2017 with its approval for type 2 diabetes, drugmakers Novo Nordisk and Eli Lilly have been battling to leapfrog each other with newer and more ...

COPENHAGEN, Dec 20 (Reuters) - Novo Nordisk (NOVOb.CO), opens new tab said on Friday it will begin a new trial of its experimental next-generation CagriSema drug in the first half of 2025 that it ...

This story was updated to add new information. The parent company of Danish drug maker Novo Nordisk said it completed its $16.5 billion purchase of Catalent, including the Bloomington operations ...

Novo Nordisk, for its part, has been working hard to enrich its cardiometabolic pipeline in areas beyond diabetes and obesity, where the company currently dominates the commercial market with its ...

Investors with a lot of money to spend have taken a bullish stance on Novo Nordisk (NYSE:NVO). And retail traders should know. We noticed this today when the trades showed up on publicly available ...

Subscribe here to receive future editions. There may be a new, unintended side effect linked to Novo Nordisk's blockbuster diabetes injection, Ozempic. Danish health authorities on Monday said ...